Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus.
It has been difficult to propagate and titrate hepatitis B virus (HBV) in tissue culture. We examined whether vesicular stomatitis virus (VSV) pseudotypes bearing HBV surface (HBs) proteins infectious for human cell lines could be prepared. For this, expression plasmids for three surface proteins, L, M, and S, of HBV were made. 293T cells were then transfected with these plasmids either individually or in different combinations. 293T cells expressing HBs proteins were infected with VSVdeltaG*-G, a recombinant VSV expressing green fluorescent protein (GFP), to make VSV pseudotypes. Culture supernatants together with cells were harvested and sonicated for a short time. The infectivities of freshly harvested supernatants were determined by quantifying the number of cells expressing GFP after neutralization with anti-VSV serum and mouse monoclonal antibodies (MAbs) against HBs protein. Among 14 cell lines tested for susceptibility to HBV pseudotype samples, HepG2, JHH-7, and 293T cells were judged to be the most susceptible. Namely, the infectious units (IU) of the culture supernatant samples neutralized with anti-VSV in the absence and presence of anti-HBs S MAbs and titrated on HepG2 cells ranged from 1,000 to 4,000 IU/ml and 200 to 400 IU/ml, respectively, suggesting the presence of VSVdeltaG*(HBV) pseudotypes. This infectivity was inhibited by treatment with lactoferrin or dextran sulfate. Pretreatment of the cells with trypsin or tunicamycin inhibited plating of the pseudotype samples. The HBV pseudotypes can be used to analyze early steps of HBV infection, including the entry mechanism of HBV.
Saha
Manujendra N
MN
Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan.
Tanaka
Atsushi
A
Jinno-Oue
Atsushi
A
Shimizu
Nobuaki
N
Tamura
Kazushi
K
Shinagawa
Masahiko
M
Chiba
Joe
J
Hoshino
Hiroo
H
D000911:Antibodies, Monoclonal / Q000276:immunology; D000998:Antiviral Agents / Q000494:pharmacology; D002460:Cell Line; D016264:Dextran Sulfate / Q000494:pharmacology; D017930:Genes, Reporter; D006031:Glycosylation; D049452:Green Fluorescent Proteins / Q000032:analysis; D006493:Heparin / Q000494:pharmacology; D006510:Hepatitis B Antibodies / Q000378:metabolism; D006801:Humans; D007781:Lactoferrin / Q000494:pharmacology; D009500:Neutralization Tests; D014357:Trypsin / Q000494:pharmacology; D014415:Tunicamycin / Q000494:pharmacology; D014721:Vesicular stomatitis Indiana virus / Q000737:chemistry* / Q000235:genetics* / Q000276:immunology / Q000502:physiology; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; C096362:L protein, hepatitis B virus; C118669:S envelope protein, hepatitis B virus; D014759:Viral Envelope Proteins; D014415:Tunicamycin; D049452:Green Fluorescent Proteins; D006493:Heparin; D016264:Dextran Sulfate; D007781:Lactoferrin; D014357:Trypsin